Boxer Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Boxer Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-75,000	Closed	-$9.09M	–	32
2017 Q1	$9.09M	Hold	75,000	–	–	1.99%	12
2016 Q4	$9.18M	Buy	+75,000	New	+$9.18M	3.55%	10

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Boxer Capital's ALXN Position: Q2 2017 in Review

Boxer Capital sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 75,000 shares — an estimated $9.09M sold.

Boxer Capital first reported a position in ALXN in Q4 2016 and held it in 2 quarters. The position peaked at $9.18M in Q4 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Boxer Capital reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Boxer Capital sold 75,000 Alexion Pharmaceuticals shares in Q2 2017, an estimated $9.09M.
Boxer Capital first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 2 quarters.
Boxer Capital's Alexion Pharmaceuticals position peaked at $9.18M in Q4 2016.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Boxer Capital's 13F filing for Q2 2017, filed 14 Aug 2017.